Hepatitis C viral dynamics during ribavirin priming differ according to prior treatment response and HCV type
Summary The mode of action of ribavirin is not completely understood. Ribavirin monotherapy has a measurable antiviral effect, which shows great variability. It might lead to an earlier steady state of plasma concentration and therefore enhance the effect of following combination treatment. The aim...
Gespeichert in:
| Veröffentlicht in: | Journal of viral hepatitis 2016-11, Vol.23 (11), p.866-872 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 872 |
|---|---|
| container_issue | 11 |
| container_start_page | 866 |
| container_title | Journal of viral hepatitis |
| container_volume | 23 |
| creator | Fülöp, B. Mihm, U. Rohde, P. Buggisch, P. Schlosser, B. Biermer, M. Brodzinski, A. Fischer, J. Böhm, S. van Bömmel, F. Sarrazin, C. Berg, T. |
| description | Summary
The mode of action of ribavirin is not completely understood. Ribavirin monotherapy has a measurable antiviral effect, which shows great variability. It might lead to an earlier steady state of plasma concentration and therefore enhance the effect of following combination treatment. The aim of this study was to evaluate the antiviral effect of ribavirin priming and its influence on sustained virologic response after combination treatment in a group of patients with different hepatitis C virus (HCV) types with or without prior treatment experience. Retrospective analysis of 75 patients (37 treatment naïve, 20 prior relapse, 16 prior nonresponse, genotype 1 present in 60 patients) from five centres who received ribavirin priming as part of an individual strategy in order to improve treatment outcome. All patients received ribavirin monotherapy with a mean dose of 14.5 mg kg−1 body weight for a mean of 28 days. After ribavirin priming, dual combination treatment with pegylated interferon alfa and ribavirin was started. The mean HCV RNA decline after ribavirin priming was 0.6 log10 IU mL−1 (P |
| doi_str_mv | 10.1111/jvh.12562 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1826709051</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1826709051</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4612-8dab4569437f2dda8391732713f4331f74231a236b46715ff835c9b951f07d793</originalsourceid><addsrcrecordid>eNp1kUtv1DAURiMEoqWw4A8gS2xgkdb29SNZohF0qEatymNYWk5sg4e8sJ3C_HucTtsFEt7YuvfcI-t-RfGS4FOSz9nu5scpoVzQR8UxAcFLWtXweHlzWmKO2VHxLMYdxgQoJ0-LIyqBiYqJ46Jf20knn3xEK3Tjg-6Q2Q-6921EZg5--I6Cb3Tu-AFNwfdLxXjnbEC6bcdglkIal94YUApWp94OCQUbp3GIFunBoPVqi9J-ss-LJ0530b64u0-Krx_ef1mty83V-cfVu03ZMkFoWRndMC5qBtJRY3QFNZFAJQHHAIiTjALRFETDhCTcuQp4Wzc1Jw5LI2s4Kd4cvFMYf802JtX72Nqu04Md56hIRYXENeYko6__QXfjHIb8u0zB4mfAMvX2QLVhjDFYp5Zd6LBXBKslA5UzULcZZPbVnXFuemseyPulZ-DsAPz2nd3_36Qutut7ZXmY8DHZPw8TOvxUQoLk6tvlubrEm0-fyZaoa_gLgsyebA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1834671434</pqid></control><display><type>article</type><title>Hepatitis C viral dynamics during ribavirin priming differ according to prior treatment response and HCV type</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Fülöp, B. ; Mihm, U. ; Rohde, P. ; Buggisch, P. ; Schlosser, B. ; Biermer, M. ; Brodzinski, A. ; Fischer, J. ; Böhm, S. ; van Bömmel, F. ; Sarrazin, C. ; Berg, T.</creator><creatorcontrib>Fülöp, B. ; Mihm, U. ; Rohde, P. ; Buggisch, P. ; Schlosser, B. ; Biermer, M. ; Brodzinski, A. ; Fischer, J. ; Böhm, S. ; van Bömmel, F. ; Sarrazin, C. ; Berg, T.</creatorcontrib><description>Summary
The mode of action of ribavirin is not completely understood. Ribavirin monotherapy has a measurable antiviral effect, which shows great variability. It might lead to an earlier steady state of plasma concentration and therefore enhance the effect of following combination treatment. The aim of this study was to evaluate the antiviral effect of ribavirin priming and its influence on sustained virologic response after combination treatment in a group of patients with different hepatitis C virus (HCV) types with or without prior treatment experience. Retrospective analysis of 75 patients (37 treatment naïve, 20 prior relapse, 16 prior nonresponse, genotype 1 present in 60 patients) from five centres who received ribavirin priming as part of an individual strategy in order to improve treatment outcome. All patients received ribavirin monotherapy with a mean dose of 14.5 mg kg−1 body weight for a mean of 28 days. After ribavirin priming, dual combination treatment with pegylated interferon alfa and ribavirin was started. The mean HCV RNA decline after ribavirin priming was 0.6 log10 IU mL−1 (P<.001). The initial viral decline depended on HCV type and previous treatment status being highest among prior relapsers (0.8 log10 IU mL−1; P=.002) and HCV type 2/3 (1.2 log10 IU mL−1; P=.05) and lowest among those with prior nonresponse (0.3 log10 IU mL−1, P=.01). IFNL4 (formerly IL28B) genotype for rs12979860 and IFNL3 genotype rs8099917 did not influence the initial viral decline. The study demonstrates a significant variability in the viral dynamics and antiviral efficacy of ribavirin monotherapy, which is mainly influenced by prior treatment status. The fact that the lowest response pattern was observed in prior nonresponder patients to pegylated interferon alfa plus ribavirin combination therapy can be taken as a hint that not only the individual interferon, but also the ribavirin sensitivity contributes significantly to the nonresponsive state.</description><identifier>ISSN: 1352-0504</identifier><identifier>EISSN: 1365-2893</identifier><identifier>DOI: 10.1111/jvh.12562</identifier><identifier>PMID: 27346846</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Antiviral Agents - administration & dosage ; Drug Therapy, Combination - methods ; Female ; Hepacivirus - isolation & purification ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - virology ; Humans ; IFNL4 ; IL28B ; individualized treatment strategies ; Male ; Middle Aged ; Retrospective Studies ; Ribavirin - administration & dosage ; ribavirin priming ; Sustained Virologic Response ; treatment experience ; Treatment Outcome ; Viral Load</subject><ispartof>Journal of viral hepatitis, 2016-11, Vol.23 (11), p.866-872</ispartof><rights>2016 John Wiley & Sons Ltd</rights><rights>2016 John Wiley & Sons Ltd.</rights><rights>Copyright © 2016 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4612-8dab4569437f2dda8391732713f4331f74231a236b46715ff835c9b951f07d793</citedby><cites>FETCH-LOGICAL-c4612-8dab4569437f2dda8391732713f4331f74231a236b46715ff835c9b951f07d793</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjvh.12562$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjvh.12562$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,778,782,1414,27907,27908,45557,45558</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27346846$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fülöp, B.</creatorcontrib><creatorcontrib>Mihm, U.</creatorcontrib><creatorcontrib>Rohde, P.</creatorcontrib><creatorcontrib>Buggisch, P.</creatorcontrib><creatorcontrib>Schlosser, B.</creatorcontrib><creatorcontrib>Biermer, M.</creatorcontrib><creatorcontrib>Brodzinski, A.</creatorcontrib><creatorcontrib>Fischer, J.</creatorcontrib><creatorcontrib>Böhm, S.</creatorcontrib><creatorcontrib>van Bömmel, F.</creatorcontrib><creatorcontrib>Sarrazin, C.</creatorcontrib><creatorcontrib>Berg, T.</creatorcontrib><title>Hepatitis C viral dynamics during ribavirin priming differ according to prior treatment response and HCV type</title><title>Journal of viral hepatitis</title><addtitle>J Viral Hepat</addtitle><description>Summary
The mode of action of ribavirin is not completely understood. Ribavirin monotherapy has a measurable antiviral effect, which shows great variability. It might lead to an earlier steady state of plasma concentration and therefore enhance the effect of following combination treatment. The aim of this study was to evaluate the antiviral effect of ribavirin priming and its influence on sustained virologic response after combination treatment in a group of patients with different hepatitis C virus (HCV) types with or without prior treatment experience. Retrospective analysis of 75 patients (37 treatment naïve, 20 prior relapse, 16 prior nonresponse, genotype 1 present in 60 patients) from five centres who received ribavirin priming as part of an individual strategy in order to improve treatment outcome. All patients received ribavirin monotherapy with a mean dose of 14.5 mg kg−1 body weight for a mean of 28 days. After ribavirin priming, dual combination treatment with pegylated interferon alfa and ribavirin was started. The mean HCV RNA decline after ribavirin priming was 0.6 log10 IU mL−1 (P<.001). The initial viral decline depended on HCV type and previous treatment status being highest among prior relapsers (0.8 log10 IU mL−1; P=.002) and HCV type 2/3 (1.2 log10 IU mL−1; P=.05) and lowest among those with prior nonresponse (0.3 log10 IU mL−1, P=.01). IFNL4 (formerly IL28B) genotype for rs12979860 and IFNL3 genotype rs8099917 did not influence the initial viral decline. The study demonstrates a significant variability in the viral dynamics and antiviral efficacy of ribavirin monotherapy, which is mainly influenced by prior treatment status. The fact that the lowest response pattern was observed in prior nonresponder patients to pegylated interferon alfa plus ribavirin combination therapy can be taken as a hint that not only the individual interferon, but also the ribavirin sensitivity contributes significantly to the nonresponsive state.</description><subject>Adult</subject><subject>Aged</subject><subject>Antiviral Agents - administration & dosage</subject><subject>Drug Therapy, Combination - methods</subject><subject>Female</subject><subject>Hepacivirus - isolation & purification</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - virology</subject><subject>Humans</subject><subject>IFNL4</subject><subject>IL28B</subject><subject>individualized treatment strategies</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Retrospective Studies</subject><subject>Ribavirin - administration & dosage</subject><subject>ribavirin priming</subject><subject>Sustained Virologic Response</subject><subject>treatment experience</subject><subject>Treatment Outcome</subject><subject>Viral Load</subject><issn>1352-0504</issn><issn>1365-2893</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kUtv1DAURiMEoqWw4A8gS2xgkdb29SNZohF0qEatymNYWk5sg4e8sJ3C_HucTtsFEt7YuvfcI-t-RfGS4FOSz9nu5scpoVzQR8UxAcFLWtXweHlzWmKO2VHxLMYdxgQoJ0-LIyqBiYqJ46Jf20knn3xEK3Tjg-6Q2Q-6921EZg5--I6Cb3Tu-AFNwfdLxXjnbEC6bcdglkIal94YUApWp94OCQUbp3GIFunBoPVqi9J-ss-LJ0530b64u0-Krx_ef1mty83V-cfVu03ZMkFoWRndMC5qBtJRY3QFNZFAJQHHAIiTjALRFETDhCTcuQp4Wzc1Jw5LI2s4Kd4cvFMYf802JtX72Nqu04Md56hIRYXENeYko6__QXfjHIb8u0zB4mfAMvX2QLVhjDFYp5Zd6LBXBKslA5UzULcZZPbVnXFuemseyPulZ-DsAPz2nd3_36Qutut7ZXmY8DHZPw8TOvxUQoLk6tvlubrEm0-fyZaoa_gLgsyebA</recordid><startdate>201611</startdate><enddate>201611</enddate><creator>Fülöp, B.</creator><creator>Mihm, U.</creator><creator>Rohde, P.</creator><creator>Buggisch, P.</creator><creator>Schlosser, B.</creator><creator>Biermer, M.</creator><creator>Brodzinski, A.</creator><creator>Fischer, J.</creator><creator>Böhm, S.</creator><creator>van Bömmel, F.</creator><creator>Sarrazin, C.</creator><creator>Berg, T.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201611</creationdate><title>Hepatitis C viral dynamics during ribavirin priming differ according to prior treatment response and HCV type</title><author>Fülöp, B. ; Mihm, U. ; Rohde, P. ; Buggisch, P. ; Schlosser, B. ; Biermer, M. ; Brodzinski, A. ; Fischer, J. ; Böhm, S. ; van Bömmel, F. ; Sarrazin, C. ; Berg, T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4612-8dab4569437f2dda8391732713f4331f74231a236b46715ff835c9b951f07d793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antiviral Agents - administration & dosage</topic><topic>Drug Therapy, Combination - methods</topic><topic>Female</topic><topic>Hepacivirus - isolation & purification</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - virology</topic><topic>Humans</topic><topic>IFNL4</topic><topic>IL28B</topic><topic>individualized treatment strategies</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Retrospective Studies</topic><topic>Ribavirin - administration & dosage</topic><topic>ribavirin priming</topic><topic>Sustained Virologic Response</topic><topic>treatment experience</topic><topic>Treatment Outcome</topic><topic>Viral Load</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fülöp, B.</creatorcontrib><creatorcontrib>Mihm, U.</creatorcontrib><creatorcontrib>Rohde, P.</creatorcontrib><creatorcontrib>Buggisch, P.</creatorcontrib><creatorcontrib>Schlosser, B.</creatorcontrib><creatorcontrib>Biermer, M.</creatorcontrib><creatorcontrib>Brodzinski, A.</creatorcontrib><creatorcontrib>Fischer, J.</creatorcontrib><creatorcontrib>Böhm, S.</creatorcontrib><creatorcontrib>van Bömmel, F.</creatorcontrib><creatorcontrib>Sarrazin, C.</creatorcontrib><creatorcontrib>Berg, T.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of viral hepatitis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fülöp, B.</au><au>Mihm, U.</au><au>Rohde, P.</au><au>Buggisch, P.</au><au>Schlosser, B.</au><au>Biermer, M.</au><au>Brodzinski, A.</au><au>Fischer, J.</au><au>Böhm, S.</au><au>van Bömmel, F.</au><au>Sarrazin, C.</au><au>Berg, T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hepatitis C viral dynamics during ribavirin priming differ according to prior treatment response and HCV type</atitle><jtitle>Journal of viral hepatitis</jtitle><addtitle>J Viral Hepat</addtitle><date>2016-11</date><risdate>2016</risdate><volume>23</volume><issue>11</issue><spage>866</spage><epage>872</epage><pages>866-872</pages><issn>1352-0504</issn><eissn>1365-2893</eissn><abstract>Summary
The mode of action of ribavirin is not completely understood. Ribavirin monotherapy has a measurable antiviral effect, which shows great variability. It might lead to an earlier steady state of plasma concentration and therefore enhance the effect of following combination treatment. The aim of this study was to evaluate the antiviral effect of ribavirin priming and its influence on sustained virologic response after combination treatment in a group of patients with different hepatitis C virus (HCV) types with or without prior treatment experience. Retrospective analysis of 75 patients (37 treatment naïve, 20 prior relapse, 16 prior nonresponse, genotype 1 present in 60 patients) from five centres who received ribavirin priming as part of an individual strategy in order to improve treatment outcome. All patients received ribavirin monotherapy with a mean dose of 14.5 mg kg−1 body weight for a mean of 28 days. After ribavirin priming, dual combination treatment with pegylated interferon alfa and ribavirin was started. The mean HCV RNA decline after ribavirin priming was 0.6 log10 IU mL−1 (P<.001). The initial viral decline depended on HCV type and previous treatment status being highest among prior relapsers (0.8 log10 IU mL−1; P=.002) and HCV type 2/3 (1.2 log10 IU mL−1; P=.05) and lowest among those with prior nonresponse (0.3 log10 IU mL−1, P=.01). IFNL4 (formerly IL28B) genotype for rs12979860 and IFNL3 genotype rs8099917 did not influence the initial viral decline. The study demonstrates a significant variability in the viral dynamics and antiviral efficacy of ribavirin monotherapy, which is mainly influenced by prior treatment status. The fact that the lowest response pattern was observed in prior nonresponder patients to pegylated interferon alfa plus ribavirin combination therapy can be taken as a hint that not only the individual interferon, but also the ribavirin sensitivity contributes significantly to the nonresponsive state.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>27346846</pmid><doi>10.1111/jvh.12562</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1352-0504 |
| ispartof | Journal of viral hepatitis, 2016-11, Vol.23 (11), p.866-872 |
| issn | 1352-0504 1365-2893 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1826709051 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Aged Antiviral Agents - administration & dosage Drug Therapy, Combination - methods Female Hepacivirus - isolation & purification Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - virology Humans IFNL4 IL28B individualized treatment strategies Male Middle Aged Retrospective Studies Ribavirin - administration & dosage ribavirin priming Sustained Virologic Response treatment experience Treatment Outcome Viral Load |
| title | Hepatitis C viral dynamics during ribavirin priming differ according to prior treatment response and HCV type |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T08%3A42%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hepatitis%20C%20viral%20dynamics%20during%20ribavirin%20priming%20differ%20according%20to%20prior%20treatment%20response%20and%20HCV%20type&rft.jtitle=Journal%20of%20viral%20hepatitis&rft.au=F%C3%BCl%C3%B6p,%20B.&rft.date=2016-11&rft.volume=23&rft.issue=11&rft.spage=866&rft.epage=872&rft.pages=866-872&rft.issn=1352-0504&rft.eissn=1365-2893&rft_id=info:doi/10.1111/jvh.12562&rft_dat=%3Cproquest_cross%3E1826709051%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1834671434&rft_id=info:pmid/27346846&rfr_iscdi=true |